ABVC BioPharma (ABVC) Q2 2026 earnings summary

Executive summary

• The company is a clinical-stage biopharmaceutical firm focused on plant-derived drugs and medical devices, with subsidiaries and joint ventures in the US, Taiwan, and other regions.

• No revenue was generated in the three or six months ended June 30, 2026, as the business is pre-commercial and relies on licensing, milestone payments, and CDMO services.

• Significant licensing agreements were executed with ForSeeCon Eye Corporation and OncoX BioPharma, but revenue recognition is pending due to valuation uncertainties.

• The company completed the legal separation of its BioKey Cayman subsidiary, with a planned distribution of 15% of BioKey shares to shareholders, though the distribution was postponed.

Financial highlights

• Net loss for Q2 2026 was $810,481, a 65% improvement from $2,332,833 in Q2 2025.

• Net loss for the six months ended June 30, 2026 was $2,500,418, down 24% from $3,277,023 in the prior year period.

• Operating expenses decreased 66% year-over-year for Q2 and 21% for the six-month period, mainly due to lower stock-based compensation.

• Cash and cash equivalents were $31,944 as of June 30, 2026, with a working capital deficit of $5,282,776.

• Net cash used in operating activities was $1,138,656 for the six months ended June 30, 2026.

Outlook and guidance

• Management is focused on improving operations, reducing expenses, and seeking additional financing to address going concern risks.

• The company aims to convert strategic investments into sustainable revenue through licensing, milestone payments, and expansion of its CDMO platform.

• Ongoing integration of subsidiaries and affiliates is expected to support future cash flows.